JP Morgan maintains overweight rating on Ascentage Pharma
JP Morgan maintained an overweight rating on Ascentage Pharma Group and cut its price target to $33.00 from $46.00.
Story updates
09:17:33 PM UTC
SquawkNews
Ascentage Pharma Group Price Target Cut to $33.00/Share From $46.00 by JP Morgan